Quark Pharmaceuticals Inc.

Fremont, CA, United States

Quark Pharmaceuticals Inc.

Fremont, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Quark Pharmaceuticals Inc. | Date: 2016-09-16

The disclosure relates to compounds, in particular siRNAs that inhibit the expression of specific human genes, for treating ocular diseases or disorders. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present disclosure also provides methods of treating and/or preventing the incidence or severity of various ocular diseases or disorders associated with the genes associated with such diseases or disorders by administering to a subject in need of treatment for such disease or disorder the compounds or pharmaceutical compositions in a therapeutically effective dose.


Patent
Quark Pharmaceuticals Inc. | Date: 2017-04-05

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.


Patent
Quark Pharmaceuticals Inc. | Date: 2015-05-27

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.


Patent
Quark Pharmaceuticals Inc. and Rutgers University | Date: 2016-08-04

The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.


Patent
Quark Pharmaceuticals Inc. | Date: 2016-08-04

Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnires disease.


Patent
Quark Pharmaceuticals Inc. | Date: 2016-08-04

The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.


Patent
Quark Pharmaceuticals Inc. | Date: 2016-07-28

Disclosed herein are double stranded nucleic acid molecules and pharmaceutical compositions comprising same useful in the treatment of, inter alia, acute and chronic inflammation, neuropathic pain, primary graft dysfunction (PGD) after lung transplantation in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA compounds, which down regulate or inhibit expression of Toll like receptor 4.


Patent
Quark Pharmaceuticals Inc. | Date: 2016-01-15

Disclosed herein are double stranded RNA molecules which have been modified to exhibit one of the following, increased activity, enhanced nuclease stability, reduced off target activity and or reduced immunogenicity, to pharmaceutical compositions comprising such compounds and to methods of use. Further disclosed is a method for the synthesis of threose nucleic acid phosphoramidites and methods of use thereof.


Patent
Quark Pharmaceuticals Inc. | Date: 2015-04-22

The present invention relates to non-invasive methods for treating diseases, disorders and injury to the central nervous system (CNS), and in particular to otic compositions and to methods of use thereof.


Patent
Quark Pharmaceuticals Inc. | Date: 2016-07-01

The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.

Loading Quark Pharmaceuticals Inc. collaborators
Loading Quark Pharmaceuticals Inc. collaborators